CJC-1295 with DAC is a long-acting synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog, which stimulates the body’s own growth hormone (GH) production. It is used for research purposes and found in some wellness programs for benefits such as increased muscle mass and fat loss, but it is not approved for human use by the FDA.
Overview and Mechanism
The “DAC” stands for Drug Affinity Complex, a modification that allows the peptide to bind to a common blood protein called albumin, dramatically extending its half-life.
- Mechanism of Action: CJC-1295 with DAC binds to GHRH receptors in the pituitary gland, signaling it to release more natural growth hormone. This results in increased levels of Insulin-Like Growth Factor 1 (IGF-1), which mediates many of the benefits.
- Half-Life and Dosing: Due to the DAC, the peptide has an extended half-life of roughly 6 to 8 days, requiring less frequent dosing, often once or twice per week. The “no DAC” version (also known as Modified GRF (1-29)) has a much shorter half-life of about 30 minutes, necessitating daily injections to maintain an effect.
- Release Pattern: CJC-1295 with DAC provides a more sustained, steady elevation of GH and IGF-1 levels, in contrast to the pulsatile (spiky) release pattern of the no-DAC version.
Potential Benefits
Users and clinical studies have reported a range of potential benefits when used as part of a structured wellness or performance program:
- Enhanced Body Composition: Increased lean muscle mass and tone, as well as reduced visceral and stubborn fat.
- Improved Recovery and Performance: Faster exercise recovery, increased strength, and better physical performance.
- Better Sleep Quality: GHRH is known to promote deep slow-wave sleep, which many users report as an early benefit.
- Anti-Aging Effects: Support for increased collagen production and skin elasticity, which may reduce the signs of aging.
- Increased Vitality: Reports of improved energy levels, mood, and mental clarity.
Potential Side Effects and Risks
Commonly reported side effects are generally mild and may include:
- Injection Site Reactions: Redness, pain, or swelling at the injection area.
- Systemic Effects: Flushing of the face, mild headaches, water retention, temporary numbness or tingling, and potential shifts in blood sugar levels.
- Prolonged Effects: The long half-life means that effects and side effects can persist longer, making dose adjustments slower and potentially leading to a higher risk of receptor desensitization over time compared to the no-DAC version.
Reviews
There are no reviews yet.